title: Clinical experiences with low-molecular weight heparins in pediatric patients.
abstract: The courses of 79 children (2 weeks to 19 years old) treated with two different low-molecular weight heparins (LMWHs)--nadroparin (n=66) and enoxaparin (n=13)--were retrospectively analysed. In 62 patients, LMWHs were given for short-term prophylaxis (1-2 weeks) during immobilization after surgery or trauma. Thirteen children with thromboembolic events received long-term prophylaxis with LMWHs for 2-18 months--six after thrombolytic therapy and seven after therapy with unfractionated heparin (UFH). Because of thromboembolic events, four patients were initially treated with LMWHs. In all patients with short-term prophylaxis, no thrombosis occurred. After thrombolytic therapy, three children had no reocclusion, two had no thrombus apposition and one had complete recanalization. In the seven patients treated with LMWHs after UFH, four had no reocclusion, two had recanalization and one had reocclusion. In all patients receiving LMWHs for initial treatment of thrombosis, no thrombus apposition, but also no recanalization, occurred. For short-term prophylaxis, nadroparin was used independent of the body weight and without determination of anti-factor Xa (anti-FXa) activity. Long-term prophylaxis was given mainly as doses of 45-100 anti-FXa U/kg resulting in anti-FXa activities between 0.2 and 0.4 U/ml. For treatment of thrombosis, doses of 200-300 anti-FXa U/kg corresponded to 0.5-1.0 anti-FXa U/ml. Side effects--slight gastrointestinal bleeding and temporary reversible hair loss--were seen in two patients. In conclusion, LMWHs proved to be efficacious and safe especially in prophylaxis of thromboembolic events in children.
authors.affiliation: Department of Pediatrics, University Hospital of Technical University, Fetscherstrasse 74, D-01307 Dresden, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Hofmann
authors.forename: R
authors.initials: R
authors.lastname: Knoefler
authors.forename: N
authors.initials: N
authors.lastname: Lorenz
authors.forename: G
authors.initials: G
authors.lastname: Siegert
authors.forename: J
authors.initials: J
authors.lastname: Wendisch
authors.forename: D
authors.initials: D
authors.lastname: Mueller
authors.forename: H
authors.initials: H
authors.lastname: Taut-Sack
authors.forename: J
authors.initials: J
authors.lastname: Dinger
authors.forename: M
authors.initials: M
authors.lastname: Kabus
mesh_terms: D000293:Adolescent; D000925:Anticoagulants / Q000008:administration & dosage* / Q000633:toxicity; D002648:Child; D002675:Child, Preschool; D017984:Enoxaparin / Q000008:administration & dosage / Q000633:toxicity; D065427:Factor Xa Inhibitors; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage* / Q000633:toxicity; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D017762:Nadroparin / Q000008:administration & dosage / Q000633:toxicity; D012189:Retrospective Studies; D013923:Thromboembolism / Q000188:drug therapy / Q000517:prevention & control; D015912:Thrombolytic Therapy; D013927:Thrombosis / Q000188:drug therapy / Q000517:prevention & control; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants; D017984:Enoxaparin; D065427:Factor Xa Inhibitors; D006495:Heparin, Low-Molecular-Weight; D017762:Nadroparin